Evidence map›Paper›PMID 34834378›Full record

ArticlePharmaceutics2021

Critical Aspects in the Preparation of Extemporaneous Flecainide Acetate Oral Solution for Paediatrics.

Antonella Casiraghi, Giorgio Centin, Francesca Selmin, Claudia Picozzi, Paola Minghetti, Davide Zanon

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Antonella CasiraghiDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0003-3683-8510
Giorgio CentinPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health IRCCS Burlo Garofolo, 34137 Trieste, Italy.
Francesca SelminDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-3680-6124
Claudia PicozziDepartment of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-5526-9782
Paola MinghettiDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Davide ZanonPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health IRCCS Burlo Garofolo, 34137 Trieste, Italy.
University of Milan · ITIRCCS Materno Infantile Burlo Garofolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The availability of liquid oral preparations compounded by pharmacists is essential to meet paediatric needs which remain unanswered by the pharmaceutical industry. Unfortunately, compendial monographs are often not available and, in many cases, pre-formulation studies (e.g., compatibility with other excipients and solubility evaluations) are not performed in-depth, leading, in some rare cases, to the inadvertent administration of a toxic dose. In this study, the preparation of an oral liquid formulation for paediatric use, containing flecainide acetate at different strengths, was considered, taking into account the possible effects of conventionally used excipients. First, the optimal vehicle was selected based on a solubility study, evidencing some unexpected formations of precipitates. As a matter of fact, the buffers commonly used for oral solutions significantly reduced flecainide solubility, and the concomitant presence of citrate buffer and methylparaben even caused the formation of non-resuspendable crystals. Then, chemical, physical, and microbiological stability were assessed. Solutions at strengths of 10 and 20 mg/mL flecainide acetate were stable up to 8 weeks when compounded by using a 40% sucrose solution as a vehicle. Microbiological data showed that the use of methylparaben was not necessary over this time period.

Indexed as

age-related dosecompatibilityextemporaneous preparationoff-labeloral deliverypreservativesolubilitystability

Identifiers

PMID34834378
PMCPMC8618881
OpenAlexW3215081576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.